# A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

> **NCT05211895** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 860 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Domvanalimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05211895
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-18
- **Primary completion:** 2028-07-12
- **Final completion:** 2030-10-01
- **Target enrollment:** 860 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05211895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05211895, "A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05211895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*